Following an “unprecedented, rigorous, multistep global consensus process,” world experts have renamed polycystic ovary syndrome to better reflect its wide-ranging effects on upward of 200 million women each year.
The condition is now called “polyendocrine metabolic ovarian syndrome,” or PMOS, to better reflect the range of symptoms patients face. The change was published this month in The Lancet, one of the world’s oldest and most prestigious peer-reviewed medical journals.
